Promising
Ibudilast: protect nerve tissue in primary progressive MS
primary progressive MS · Microglia / innate immunity in the CNS
A controlled phase 2 trial was positive. Phase 2 trials are small and often measure early markers, so this is a signal, not proof.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 255
Deciding trials (phase 2): 1 met, 0 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosisdecides the statusMet main goal
Phase 2 · 2013 · Placebo-controlled · MSFT-NCT01982942
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as Promising
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error